Fraunhofer-Gesellschaft

Publica

Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Software-based planning of ultrasound and CT-guided percutaneous radiofrequency ablation in hepatic tumors

 
: Amerongen, M.J. van; Mariappan, P.; Voglreiter, P.; Flanagan, R.; Jenniskens, S.F.M.; Pollari, M.; Kolesnik, M.; Moche, M.; Fütterer, J.J.

:
Volltext ()

International journal of computer assisted radiology and surgery 16 (2021), Nr.6, S.1051-1057
ISSN: 1861-6410
ISSN: 1861-6429
Englisch
Zeitschriftenaufsatz, Elektronische Publikation
Fraunhofer FIT ()

Abstract
Objectives
Radiofrequency ablation (RFA) can be associated with local recurrences in the treatment of liver tumors. Data obtained at our center for an earlier multinational multicenter trial regarding an in-house developed simulation software were re-evaluated in order to analyze whether the software was able to predict local recurrences.
Methods
Twenty-seven RFA ablations for either primary or secondary hepatic tumors were included. Colorectal liver metastases were shown in 14 patients and hepatocellular carcinoma in 13 patients. Overlap of the simulated volume and the tumor volume was automatically generated and defined as positive predictive value (PPV) and additionally visually assessed. Local recurrence during follow-up was defined as gold standard. Sensitivity and specificity were calculated using the visual assessment and gold standard.
Results
Mean tumor size was 18 mm (95% CI 15–21 mm). Local recurrence occurred in 5 patients. The PPV of the simulation showed a mean of 0.89 (0.84–0.93 95% CI). After visual assessment, 9 incomplete ablations were observed, of which 4 true positives and 5 false positives for the detection of an incomplete ablation. The sensitivity and specificity were, respectively, 80% and 77% with a correct prediction in 78% of cases. No significant correlation was found between size of the tumor and PPV (Pearson Correlation 0.10; p = 0.62) or between PPV and recurrence rates (Pearson Correlation 0.28; p = 0.16).
Conclusions
The simulation software shows promise in estimating the completeness of liver RFA treatment and predicting local recurrence rates, but could not be performed real-time. Future improvements in the field of registration could improve results and provide a possibility for real-time implementation.

: http://publica.fraunhofer.de/dokumente/N-636608.html